Potassium depolarization and raised calcium induces α-synuclein aggregates

Neurotoxicity Research

Volumn 23, Issue 4, 2013, Pages 378-392

  Follett, Jordan ^a   Darlow, Bonnie ^a   Wong, Mathew B ^a   Goodwin, Jacob ^a   Pountney, Dean L ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Synuclein; Calcium; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; POTASSIUM; POTASSIUM CHLORIDE; TRIMETHADIONE;

ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CELL INCLUSION; CELL LINE; CELL STRAIN HEK293T; CELL STRAIN SH-SY5Y; CONTROLLED STUDY; DEPOLARIZATION; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN AGGREGATION; QUANTITATIVE ANALYSIS;

ALPHA-SYNUCLEIN; CALCIUM; CELL LINE, TUMOR; HEK293 CELLS; HUMANS; INTRACELLULAR FLUID; POTASSIUM CHLORIDE;

EID: 84876293052     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-012-9366-z     Document Type: Article

References (54)

1. Berjukow S, Döring F, Froschmayr M, Grabner M, Glossmann H, Hering S (1996) Endogenous calcium channels in human embryonic kidney (HEK293) cells. Br J Pharmacol 118(3):748-754
2. Bezprozvanny I (2009) Calcium signaling and neurodegenerative diseases. Trends Mol Med 15:89-100
3. 2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharm 48:540-549
4. Breydo L, Wu JW, Uversky VN (2012) A-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 1822:261-285
5. Bruseell R Jr, Eliezer D (2003) A structural and functional role for 11-mer repeats in alpha synuclein and other exchangeable lipid binding proteins. J Mol Biol 329:763-778
6. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P (2001) Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 70:7033-7040
7. Chin LS, Olzmann JA, Li L (2010) Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochem Soc Trans 38:144-149
8. Conway K, Lee S, Rochet J, Ding T, Williamson R, Lansbury P Jr (2000) Acceleration of oligomerization, not fibrilization, is a shared property of both α synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA 99:571-576
9. Cookson MR (2009) alpha-Synuclein and neuronal cell death. Mol Neurodegener 4:9
10. 2+ transients. Brain Res 1031:174-184
11. Desai A et al (2006) Human neuroblastoma (SH-SY5Y) cell culture and differentiation in 3-D collagen hydrogels for cell-based biosensing. Biosens Bioelectron 21:1483-1492
12. Dohm CP, Kermer P, Bahr M (2008) Aggregopathy in neurodegenerative diseases: mechanism and therapeutic implication. Neurodegener Dis 5:321-338
13. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT (2007) Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 170(5):1725-1738
14. 2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc Drugs Ther 11:723-739
15. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404:394-398
16. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT (2007) The impact of the E46K mutant on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46:7107-7118
17. Freedman SB et al (1984) Identification and characterization of voltage-sensitive calcium channels in neuronal clonal cell lines. J Neurosci 4(6):1453-1467
18. Garcia-mata R, Bebok Z, Sorscher EJ, Sztul ES (1999) Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J Cell Biol 146:1239-1254
19. Goodwin J, Nath S, Engelborghs Y, Pountney DL (2012) Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. Neurochem Int. http://dx.doi.org/10.1016/j.neuint.2012.11.004
20. Heady TN, Gomora JC, Macdonald TL, Perez-Reyes E (2001) Molecular pharmacology of t-type calcium (II) channels. Jpn J Pharmacol 85:339-350
21. 2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111:1192-1201
22. Huguenard JR (1996) Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 58:329-348
23. Jellinger KA (2009) Formation and development of Lewy pathology: a critical update. J Neurol 256(Suppl 3):270-279
24. Johnston JA, Ward CL, Kopito RR (1998) Aggresomes: a cellular response to misfolded proteins. J Cell Biol 14:1883-1898
25. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai WP, El-Agnaf O, Richter-Landsberg C, Jensen PH (2009) α-Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 284:10211-10222
26. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108
27. Larsen KE et al (2006) α-Synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26:11915-11922
28. Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, Ishii T, Komatsu M, Eissa NT (2012) Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 287:19687-19698
29. Lowe R, Pountney DL et al (2004) Calcium (II) selectively induces α-synuclein annular oligomers via interaction with C-terminal domain. Protein Sci 13(12):3245-3252
30. Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350. doi: 10.1038/cddis.2012.94
31. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6:337-350
32. McLean PJ, Kawamata H, Hyman BT (2001) α-Synuclein enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in Primary neurons. Neuroscience 104:901-912
33. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218-229
34. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20:3214-3220
35. Nath S, Goodwin J, Engelborghs Y, Pountney DL (2011) Raised calcium promotes α-synuclein aggregate formation. Mol Cell Neurosci 46:516-526
36. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65:66-79
37. Nielsen MS, Vorum H, Lindersson E, Jensen PH (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem 276:22680-22684
38. Nikoletopoulou V, Tavernarakis N (2012) Calcium homeostasis in aging neurons. Front Genet 3:200
39. Park SM, Jung HY, Kim TD, Kim J (2002) Distinct roles of the N-terminal-binding domain and the C-terminal solubilising domain of alpha-synclein, a molecular chaperone. J Biol Chem 277:28512-28520
40. Polymeropoulos M, Lavedan C, Leroy E, Ide E, Deheia A, Rutru A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos S, Chandrasekharappa S, Athanassiadou A, Papetropoulous T, Johnson G, Lazzarini M, Duoisin C, Di-Iorio G, Golbe I, Nussbaum R (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047
41. Pountney D, Voelcker N, Gai W (2005) Annular alpha synuclein oligomers are potentially toxic agents in alpha synucleinopathy. Hypothesis. Neurotox Res 7:59-67
42. Rang HP (2001) Pharmacology, 4th edn. Churchill Livingstone, New York
43. Reeve HL, Vaughan PF, Peers C (1994) Calcium channel currents in undifferentiated human neuroblastoma (SH-SY5Y) cells: actions and possible interactions of dihydropyridines and omega-conotoxin. Eur J Neurosci 6:943-952
44. Riascos D et al (2011) Age-related loss of calcium buffering and selective neuronal vulnerability in Alzheimer's disease. Acta Neuropathol 122:565-576
45. Søgaard R, Ljungstrøm T, Pedersen KA, Olesen SP, Jensen BS (2001) KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol 280:C859-C866
46. Sonnier H, Kolomytkin OV, Marino AA (2000) Resting potential of excitable neuroblastoma cells in weak magnetic fields. Cell Mol Life Sci 57:514-520
47. Talley E, Cribbs LL, Lee J-H, Daud A, Perez-Reyes E, Bayliss DA (1999) Differential distribution of three members of a gene family encoding low voltage-activated (t-type) calcium channels. J Neurosci 19:1895-1911
48. Uversky VN, Eliezer D (2009) Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10:483-499
49. Wen X et al (2011) T-type calcium channel expression in cultured human neuroblastoma cells. Neural Regen Res 6(31):2405-2409
50. Wildburger NC, Lin-Ye A, Baird MA, Lei D, Bao J (2009) Neuroprotective effects of blockers for T-type calcium channels. Mol Neurodegener 4:1-8
51. Wojda U, Salinska E, Kuznicki J (2008) Calcium ions in neuronal degeneration. IUBMB Life 60(9):575-590
52. Yamada T, McGeer PL, Baimbridge KG, McGeer EG (1990) Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526:303-307
53. Yunker MA (2003) Modulation and pharmacology of low voltage-activated T-type calcium channels. J Bioenerg Biomembr 35:577-598
54. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha synuclein causes Parkinson's disease and Lewy Body Dementia. Ann Neurol 55:164-173